Nuvisan logo
  • contact us navContact Us
  • search navSearch
Let's connect

Want to discuss your project or have any questions?

Multicentre patient studies

Professional clinical development support for your multicentre phase 1–2 trials

Nuvisan conducts small multicentre clinical trials in patient populations. A pivotal step in early clinical development is the proof-of-concept (PoC) study in patients and it is crucial to meet this milestone as early as possible. Nuvisan provides all the services needed to help make your drug development a success story.

We deliver comprehensive product development services for multicentre phase 1–2 clinical research studies for investigational medicinal products (IMPs) (e.g. biologics) and medical devices. With a strong foundation in clinical trial conduct and extensive expertise, we support our clients in overcoming the challenges and complexities of conducting clinical programs.

Doctor consulting with a patient about clinical trial recruitment

Therapeutic/multi-centric framework

Our broad range of clinical development solutions covers diverse service offerings in different therapeutic areas, with a proven history in respiratory studies. Additionally, we provide flexible outsourcing models tailored to meet the unique needs of each customer. Nuvisan coordinates the clinical conduct of multicentre clinical studies, with a focus on countries neighbouring Germany, e.g. Austria and Poland.

Reliable study feasibility

At Nuvisan, we approach study feasibility as a dynamic, ongoing process and have a detailed understanding of the local research landscape. We collaborate closely with potential investigators and their networks and we continuously collect valuable insights and share them with study sponsors. This helps ensure well-informed decisions are made at every step of the program. We also have a profound understanding of critical success factors, especially the importance of communication and of the right selection of study sites, training of investigators and focusing clinical monitoring on what is essential.

Related topics & resources

Patient room with white interior for clinical trials

Clinical Pharmacology Unit 

Our clinical pharmacology unit conducts early phase clinical trials for our clients for over 40 years.

Learn more
Clinical Operations team discussing clinical trial related planning

Clinical operations

Check out our clinical operations support capabilities.

Learn more
Business people join puzzle pieces in office, concept of cinical trial supply services

Our trial solutions

Discover how our comprehensive clinical trial services can support your efforts. 

Learn more

Frequently asked questions (FAQs)

  • What is a multicentre clinical trial in patients?
    A multicentre phase 1 clinical trial in patients is an early-stage study of a new investigational medicinal product conducted at several specialised clinical sites at the same time. Instead of running at a single site, multiple phase 1 units enrol eligible patients under one shared protocol. Multicentre phase 1 trials can support faster recruitment, strengthen the data set and help improve the efficiency of early clinical development.
  • What is the objective of a phase 2 study?
    In phase 2, the investigational product is administered to a larger group of patients to generate initial data on efficacy. Safety and optimal dosing continue to be evaluated. This phase informs the design of later pivotal trials.
  • How is patient safety ensured?
    Clinical trials can only proceed after approval by an independent ethics committee and the relevant regulatory authorities. In Germany, this includes the Bundesinstitut für Arzneimittel und Medizinprodukte, for example. Patient safety is monitored throughout the study, and participation is voluntary, with the right to withdraw at any time.
  • What is the difference between phase 1 drug trials and early feasibility device studies?
    Early-stage drug trials (phase 1) and early medical device investigations can both take place in patients, particularly in serious conditions or where unmet medical needs exist. Drug studies focus on safety, tolerability and dose escalation. Early device studies assess safety, technical performance and procedural feasibility under strict regulatory oversight.
  • How do you assess study feasibility?
    Study feasibility should be treated as an ongoing process rather than a one-off assessment. Close collaboration with investigators and their networks provides insight into the local research landscape and supports informed decisions throughout the study. Key areas of focus include selecting the right sites, training investigators effectively, maintaining clear communication and applying targeted clinical monitoring.

Contact us

Nuvisan is committed to protecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:
You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Email us

hello@nuvisan.com

Talk to us

talk icon
+49 731 9840 0 

Our locations

location icon

Neu-Ulm (headquarters)

Wegenerstrasse 13

89231 Neu-Ulm

Germany

Berlin

Muellerstrasse 178

13353 Berlin

Germany

Sophia Antipolis

2400 route des Colles

06410 Biot

France

Grafing

Am Feld 32

85567 Grafing

Germany

Waltrop

Im Wirrigen 25

45731 Waltrop

Germany

For concerns about pharmaceuticals or adverse drug-related events, contact us at: complaints@nuvisan.com
 
v.1.1.1437